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Abstract 
Continuous monitoring of the electrocardiogram (ECG) is a common intervention in people admitted 
to hospital, especially when the cause of admission has a cardiovascular origin.  Although widely 
considered a simple, routine procedure, ECG monitoring requires expert knowledge and sound 
clinical judgement for it to be used safely.   Incorrect use of monitoring equipment can result in 
suboptimal care, and adverse patient outcomes, including death.  Patient selection, correct set-up of 
equipment, and careful alarm management are all important in ensuring that monitoring is 
conducted safely.  In this article, the first of two, the indications for monitoring are discussed and 
evaluated.  For most patients, this will be arrhythmia monitoring; however, some will have an 
additional requirement for ischaemia or QT interval monitoring.  The practical aspects of ECG 
monitoring will be addressed in the second article in this series.   
 
Introduction 
Continuous monitoring of the electrocardiogram (ECG) is a common intervention in people admitted 
to hospital for a planned cardiac procedure, or with a cardiovascular emergency (Adam et al, 2017).  
Although widely considered a simple, routine procedure, ECG monitoring requires expert knowledge 
and sound clinical judgement for it to be used safely (Hatchett, 2017).  Incorrect use of monitoring 
equipment can result in suboptimal care, and adverse patient outcomes (Spratt, 2016).  Deaths 
resulting from poor monitoring practice have been reported (Pelter and Drew, 2015).   
Nurses are the health care workers most often responsible for initiating and managing patient 
monitoring; a sound knowledge of this area of practice is therefore essential.  Nurses must be able 
to assess monitoring needs, place electrodes correctly, and manage monitor setup and alarms 
(Sandau and Smith, 2009).  They must also decide which of the various monitoring types to initiate; 
for most patients this will be simple arrhythmia detection, but in some cases, there will be an 
additional indication for ischaemia or QT interval monitoring (Sangkachand et al, 2011).  Duration of 
monitoring must be appropriate, and unnecessary monitoring avoided (Sandau et al, 2017).   
This is the first of two articles evaluating the core knowledge that nurses need to manage 
continuous ECG monitoring safely and effectively.  In this first article, the various indications for 
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monitoring are discussed and evaluated.  In the second article, practical issues relating to electrode 
placement and lead selection will be examined, as well as the issues surrounding alarm 
management.  Readers should note that ECG interpretation is beyond the scope of these articles, 
and will not be discussed.   
 
Arrhythmia detection 
The most common indication for continuous ECG monitoring is arrhythmia detection (Sandau et al, 
2017).  Arrhythmias are common in the acutely unwell, and have varying consequences (Bennett, 
2013).  Supraventricular arrhythmias, such as atrial fibrillation, often complicate cardiac admissions, 
causing haemodynamic instability and delaying recovery (Kirchof et al, 2016).  While rarely life-
threatening, early recognition allows timely treatment and improves patient outcomes (Pitcher and 
Nolan, 2015).  In contrast, atrioventricular (AV) blocks and ventricular arrhythmias often have more 
serious sequalae (Adam et al, 2017).  These arrhythmias are common complications of cardiac 
events, in particular acute coronary syndromes (ACS), and are a leading cause of death in this 
context (Hreybe and Saba, 2009).  Early detection facilitates life saving measures such as 
defibrillation, one of the few interventions shown to improve outcomes after cardiac arrest 
(Resuscitation Council UK, 2016).  Table 1 lists the most common indications for arrhythmia 
monitoring in patients admitted to cardiac units and wards, and is taken from recently published 
practice guidelines (Sandau et al, 2017).  Most indications for arrhythmia monitoring are given a 
class I rating by the guidelines, the highest level of recommendation. 
Given the importance of arrhythmia detection, it might be tempting to monitor every patient, 
regardless of perceived risk.  Unfortunately, this is neither practical nor desirable.  Outside of critical 
care areas, there are insufficient resources to monitor every patient.  Unnecessary monitoring may 
result in inappropriate resource allocation; high risk patients may be denied monitoring if all 
available equipment is in use (Funk et al, 2010).  Unnecessary ECG monitoring may also be 
detrimental to the patient monitored.  Unless telemetry is available, ECG monitoring restricts patient 
movement, and ability to mobilise.  This increases the risk of immobility related complications such 
as chest infection and pressure damage (Allen et al, 1999).  Monitoring may also cause the patient 
anxiety, especially when a good rationale for its use cannot be given (Hatchett, 2017).  According to 
Sandau et (2017), situations where routine arrhythmia monitoring is not indicated include: - 
• Low risk and non-cardiac chest pain 
• After non-urgent primary coronary intervention (PCI), without complications  
• After routine diagnostic coronary angiography 
• Chronic, rate controlled atrial fibrillation 
• Asymptomatic sinus bradycardia 
• Wenckebach AV block without symptoms, or transient AV block due to vagal stimulation.  
• Patients with an existing pacemaker, implantable cardioverter defibrillator (ICD), or wearable 
cardiac defibrillator, admitted for an unrelated cause 
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Patient population Duration / notes 
Class I: monitoring should be performed 
Intermediate to high risk 
suspected ACS, or confirmed 
STEMI 
At least 24-48 hours, or until ACS ruled out.  See below for post-
revascularisation guidance. 
After MI, with successful 
revascularisation 
At least 12-24 hours 
After MI, without reperfusion or 
revascularization 
At least 24-48 hours, and until no further evidence of ongoing modifiable 
ischaemia or electrical instability 
Vasospastic angina Until symptoms resolved 
Apical ballooning syndrome Until symptoms resolved 
Newly diagnosed, critical left 
main stem lesion  
Until revascularized 
After open heart surgery At least 48-72 hours in uncomplicated cases.  Duration of admission if high 
risk of post-operative AF (e.g. elderly, left atrial enlargement, mitral valve 
disease, heart failure, hypertension, history of AF) 
Transcatheter structural 
interventions 
Depends on procedure, device and patient factors.  At least 3 days 
recommended following transcatheter aortic valve implantation. 
Resuscitation from cardiac arrest, 
or unstable ventricular 
arrhythmias 
Until ICD implantation, or resolution of underlying cause if believed to be 
transient and reversible.  If further in-patient therapy planned, e.g. drug 
initiation or ablation, continue monitoring until successful. 
ICD shocks requiring hospital 
admission 
Until the precipitating event is successfully treated.  
New onset or recurrent atrial 
fibrillation/flutter 
Until patient is haemodynamically stable following suitable treatment, for 
example adequate rate control or cardioversion.  
Symptomatic sinus bradycardia Until a stable heart rhythm and rate have been restored.  This often 
requires permanent pacing unless a reversible cause is found. 
Third-degree AV block, with or 
without symptoms. 
As above. 
Second-degree AV block with 
symptoms, or due to distal 
conduction system disease. 
As above. 
Syncope of suspected cardiac 
origin 
At least 24 hours.  Monitoring may reveal cause of syncope, e.g. asystolic 
pauses, AV block, ventricular arrhythmia. 
After catheter ablation of cardiac 
arrhythmia 
Depends on procedure and patient: May not be required following simple 
SVT ablation.  12-24 hours recommended for patients with co-morbidity 
undergoing complex ablation (e.g. AF, VT). 
Temporary pacing Until pacing is no longer necessary, or a permanent pacemaker is 
implanted. 
After permanent pacemaker 
implantation 
12 to 24 hours if no consistent, intrinsic, stable heart rhythm (e.g. 
underlying asystole).  Consider in non-pacing dependent patient to detect 
early complications (e.g. lead displacement). 
Acute decompensated heart 
failure 
Until precipitating event (e.g. volume overload, ischaemia) is successfully 
treated.   
Class IIa: monitoring is reasonable 
After non-urgent PCI, with 
complications  
A minimum of 24 hours, or until complication is resolved 
Infective endocarditis Likely to be beneficial in patients with evidence of conduction 
abnormalities, heart failure, or high-risk features at echocardiogram 
Table 1: Cardiac conditions requiring arrhythmia monitoring (Sandau et al, 2017) 
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Myocardial ischaemia 
The ECG plays a key role in the diagnosis of myocardial ischaemia (Houghton and Gray, 2014).  One 
of the most important markers of ischaemia is deviation of the ST-segment, the short section of 
baseline that joins the end of the QRS complex to the beginning of the T-wave (figure 1).  On a 
normal ECG, the ST-segments are isoelectric, meaning that they sit at the same level as the other 
parts of the electrical baseline (especially the TP-segment) (Aehlert, 2011).  During myocardial 
ischemia, elevation or depression of the ST-segment may occur; this information has diagnostic and 
prognostic significance (Morris and Brady, 2009).   
 
Figure 1. ECG waveforms, intervals and segments 
 
Because sustained ischaemia can result in myocardial infarction (MI), and loss of functioning heart 
muscle, it is important to detect these changes early, so that treatment can be initiated (Thygesen et 
al, 2012).  Although the 12-lead ECG is the standard diagnostic tool for the diagnosis of ischaemia, it 
has an important limitation; it records electrical activity for a brief moment in time only 
(Sangkachand et al, 2011).  During an ischaemic episode, the initial ECG may be normal or non-
diagnostic, and may develop diagnostic features as time elapses (Houghton and Gray, 2014).  Serial 
12-lead ECGs are recommended by practice guidelines to capture these changes, however between 
these recordings significant events may be missed (Sandau et al, 2017; Thygesen et al, 2012).   
Continuous monitoring of the ST-segment is possible on many modern patient monitors, and allows 
real-time detection of ST depression and ST elevation (Bovino et al, 2015).  This can be useful in 
patients admitted with suspected ischaemia, but no ECG changes, as well as situations where there 
is a high risk of silent ischaemia, for example in patients who are sedated and ventilated following 
cardiac surgery (Sangkachand et al, 2011).   During non-ST-elevation ACS, the detection of ST-
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segment changes can aid risk categorisation and decision making, primarily about whether to 
proceed with urgent coronary angiography (Carmo et al 2011).   
Common indications for ST-segment monitoring are listed in table 2.  Although these indications are 
fairly broad, ST-segment monitoring is under-used in clinical practice (Patton and Funk, 2001; Funk 
et al, 2010).  The reasons for this include lack of awareness, scarcity of resources, and limited 
support from physicians.  Readers will note that there are no class I indications for ST-segment 
monitoring; this reflects concerns about inappropriate alarms (discussed in the second article), 
rather than a lack of evidence for this type of monitoring (Sandau et al, 2017).  As with arrhythmia 
detection, ST-segment monitoring is not recommended following routine angiography, 
uncomplicated PCI, or low-risk and non-cardiac chest pain (Sandau et al, 2017). 
 
Patient population Duration / notes 
Class IIa: monitoring is reasonable 
Early-phase ACS for intermediate to high risk 
NSTEACS or ST elevation MI (STEMI) 
At least 24-48 hours, or until ACS ruled out 
After MI without revascularisation At least 24-48 hours, and until no further evidence 
of ongoing modifiable ischaemia or electrical 
instability 
Newly diagnosed left main coronary artery lesion Until revascularized 
Vasospastic angina May be useful in documenting transient ST-segment 
changes until diagnosis confirmed and condition 
stable 
After non-urgent PCI with complications A minimum of 24 hours, or until complication is 
resolved 
During open heart surgery Duration of procedure 
Class IIb: monitoring may be considered 
After MI with successful revascularisation 12-24 hours 
During apical ballooning syndrome Until symptoms resolved 
During targeted temperature management If cause of arrest thought to be myocardial 
ischaemia. Continue until therapy terminated. 
After open heart surgery while patients are 
intubated and sedated 
Until patient able to recognise and report symptoms 
of ischaemia 
During acute decompensated heart failure with an 
ischaemia origin 
Until precipitating event has been successfully 
treated.  
In patients with acute stroke at increased risk of 
cardiac events 
24-48 hours 
Table 2. Recommendations for continuous ST-segment monitoring (Sandau et al, 2017) 
 
Detection of QT interval prolongation 
The QT interval is the time from the start of the QRS complex to the end of the T-wave, and reflects 
ventricular depolarisation and repolarisation (Garcia, 2015) (figure 1).  Because repolarisation 
shortens as heart rate increases, the QT interval is shorter at higher heart rates, and longer at slower 
ones (Pickham and Drew, 2008).  To facilitate evaluation, the interval is corrected for heart rate; the 
corrected QT (QTc) is a calculation of how long the QT interval would be at a heart rate of 60 beats 
per minute.  A normal QTc is less than 450ms in men, and less than 460ms in women (Rautaharju et 
al, 2009).  Prolongation of this interval is associated with Torsades de Pointes (TdP), a type of 
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polymorphic VT that can cause cardiac arrest and sudden cardiac death (Roden, 2008).  Prevention 
of TdP is the primary rationale for QT interval monitoring; the risk of this arrhythmia increases 
significantly when the QTc exceeds 500ms (Bennett, 2013). 
Although both depolarisation and repolarisation of the ventricles determines the QT interval, 
prolongation of the QTc in clinical practice is predominantly driven by delayed repolarisation.  In the 
cardiac cell, repolarisation occurs when potassium ions leave the cell via channels in the cell 
membrane (Klabunde, 2012).  Factors which impede normal ion movement delay repolarisation, and 
increase the risk of TdP.  These factors include inherited diseases of cardiac ion channels, in 
particular Long QT Syndrome (LQTS), electrolyte imbalance, and drugs that affect ion channel 
function (Abrams and MacRae, 2014).  Women and elderly people are more at risk, as are those with 
impaired kidney or liver function (Drew et al, 2010).   A full list of risk factors for TdP can be found in 
table 3, whilst examples of drugs that prolong the QT interval are listed in table 4.  Many of these are 
commonly used on cardiac units and wards, especially the antiarrhythmic drugs (Pickham et al, 
2010).  A full list of QT-prolonging drugs can be found at www.crediblemeds.org, a database 
maintained by the Arizona Centre for Education and Research on Therapeutics.  A mobile phone app 
is also available from the same website. 
 
Older age 
Female gender 
Structural heart disease 
Bradycardia or long pauses 
Hypokalaemia / hypomagnesaemia (moderate to severe) 
Malnutrition electrolyte disorders 
Renal or hepatic impairment 
Long QT syndrome or family history of sudden cardiac death 
Use of QT prolonging drugs 
Table 3.  Risk factors for Torsades de Pointes tachycardia (Drew et al, 2010) 
 
 
Drug class Examples  
Anaesthetic Propofol, sevoflurane 
Antiarrhythmic Amiodarone, flecainide, sotalol 
Antibiotic Azithromycin, ciprofloxacin, erythromycin 
Antidepressant  Citalopram, escitalopram 
Antiemetic Domperidone, ondansetron 
Antifungal Fluconazole, pentamidine 
Antimalarial Chloroquine, halofantrine 
Antipsychotic Haloperidol, chlorpromazine 
Opioid Methadone 
Table 4. Examples of drugs that prolong the QT interval (Arizona Centre for Education and 
Research on Therapeutics, 2017) 
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To reduce the risk of TdP, cardiac patients should be assessed for risk factors at admission, and the 
QTc should be documented.  QT interval monitoring should be instigated for high risk individuals, in 
addition to arrhythmia monitoring (Pickham and Drew, 2008).  Table 5 lists common indications for 
QT interval monitoring, taken from current practice guidelines.  Note that QT interval monitoring is 
not recommended when giving non-antiarrhythmic QT-prolonging drugs if the patient has no risk 
factors for TdP, and no history of QT prolongation (Sandau et al, 2017).  As with the ST-segment, QT 
interval monitoring is often under-used in clinical practice (Funk et al, 2010). 
 
Patient population Duration / notes 
Class I: monitoring recommended 
Patients started on antiarrhythmic drugs 
with a known risk of TdP  
(e.g. dofetilide, ibutilide, sotalol, 
disopyramide, procainamide, quinidine).   
48-72 hours suggested.  Consider changes in QT interval, drug half-
life, renal/hepatic function, presence of QT-related arrhythmias 
when deciding duration. 
Patients with a history of prolonged QT, or 
with general risk factors for TdP, who are 
started on non-antiarrhythmic drugs with 
a known risk of TdP. 
Consider changes in QT interval, drug half-life, renal/hepatic 
function, presence of QT-related arrhythmias when deciding 
duration. 
Patients undergoing targeted temperature 
management 
QT monitoring recommended until temperature normalised, QTc 
in normal range, and no QT-related arrhythmias 
Patients with inherited LQTS who present 
with unstable ventricular arrhythmias or 
who have medically/metabolically 
induced QT prolongation 
QT monitoring recommended until ventricular arrhythmias are 
stabilised, exacerbating medical/metabolic condition is reversed, 
and QTc returns to baseline.  
Patients with moderate to severe 
hypokalaemia or hypomagnesemia who 
have additional risk factors for TdP 
QTc monitoring is recommended until electrolytes are normalized 
and there is no evidence of QT-related arrhythmias 
Patients with overdose of a drug known to 
cause TdP, or an overdose of unknown 
drug(s) 
QTc monitoring is recommended until QT-prolonging drug levels 
have decreased, unknown drug has been identified as non–QT-
prolonging, QTc interval is in normal range, and no evidence of QT-
related arrhythmias 
 
Class IIa: Monitoring is reasonable 
 
Patients with a history of prolonged QT, or 
with general risk factors for TdP, who are 
started on non-antiarrhythmic drugs with 
a possible risk of TdP. 
Consider changes in QT interval, drug half-life, renal/hepatic 
function, presence of QT-related arrhythmias when deciding 
duration. 
Class IIb: Monitoring may be considered 
 
Patients started on antiarrhythmic drugs 
with a possible risk of TdP (e.g. 
amiodarone, dronedarone, flecainide).     
Consider changes in QT interval, drug half-life, renal/hepatic 
function, presence of QT-related arrhythmias when deciding 
duration. 
Table 5. Indications for QT interval monitoring (Sandau et al, 2017) 
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Conclusion 
ECG monitoring can be a lifesaving intervention when used appropriately, however patients must be 
carefully selected, and the right type of monitoring instigated.  Many patients will need rhythm 
monitoring as arrhythmias are a common complication among cardiac patients.  Other individuals 
will need additional assessment of the ST-segment or QTc, which tend to be under-monitored in 
clinical practice.  Monitoring is not required in low risk patients undergoing routine procedures, and 
can be detrimental in these circumstances.  We conclude our examination of this topic in the second 
part of this article, which will examine the practicalities of ECG monitoring. 
 
Key points 
• The main indication for continuous ECG monitoring is arrhythmia detection.  This is a class I 
indication for many cardiac patients in current practice guidelines.  Detection of arrhythmias can 
prevent clinical deterioration, and ensure timely treatment.  This is especially important in 
arrhythmias that cause cardiac arrest, such as ventricular tachycardia.  
• Some patients will also have an indication for ST-segment monitoring, in particular those with 
suspected ACS but no ECG changes.  ST-segment monitoring is also useful in situations where 
there is a high risk of silent ischaemia.   
• The third form of ECG monitoring is assessment of the QT interval.  QT interval prolongation is 
common in patients admitted to cardiac units, and is a risk factor for Torsades de Pointes (TdP), 
and sudden cardiac death.  The risk of TdP should be assessed at admission, and QT interval 
monitoring instigated if it is high, or if high risk medication is commenced. 
• Careful patient assessment is required to determine which type of monitoring is appropriate, if 
any; monitoring is not required in low risk individuals undergoing routine procedures.  
Monitoring of the ST-segment and QT interval tend to be under-used in clinical practice. 
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